Recruiting in China

Sanofi-aventis To Establish New Consumer Healthcare JV In China

dacare — Mon, 01 Feb 2010 21:59:07 +0800

Published: 29-Jan-2010

Sanofi-aventis has signed agreements with Minsheng Pharmaceutical to form a new consumer healthcare joint venture (JV). Sanofi-aventis will obtain a majority equity stake in the new entity. The agreements were signed in the presence of senior leaders of the Hangzhou municipal government.

The proposed Sanofi-aventis-Minsheng joint venture will primarily focus on vitamins and mineral supplements (VMS).

Recently, Sanofi-aventis had announced its planned acquisition of Chattem, a manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements in the US.

Hanspeter Spek, president of global operations at Sanofi-aventis, said: “We are pleased to take a significant step toward establishing the new consumer healthcare joint venture with Minsheng, our long-standing partner. Combined with our leadership position in vaccines, we will continue to contribute to preventative healthcare in China. Entering the world’s second largest consumer healthcare market is also a strategic move for Sanofi-aventis to consolidate its position in consumer healthcare.”

Zhu Fujiang, chairman of Minsheng Pharmaceutical, said: “We are equally excited about the prospect of forming the new consumer healthcare joint venture with Sanofi-aventis, after more than ten years of successful partnership.Sanofi-aventis is an energetic and dynamic company. His success with pharmaceuticals and vaccines has demonstrated his strong marketing capability.

"We hope that once materialized, the new venture will revitalize our consumer healthcare business and expand the reach of our products to benefit more consumers. We also hope that the new venture will serve as a platform for us to develop more health products in order to contribute to the local economy and meet consumer needs.”

Glaxo to cut 3,000 jobs as focus shifts to emerging markets

dacare — Mon, 01 Feb 2010 21:57:41 +0800

GlaxoSmithKline is poised to announce cuts of more than 3,000 jobs this week at its European and US operations as the focus shifts from stagnant Western markets to China, emerging Asia, and Latin America.

By Ambrose Evans-Pritchard
Published: 6:51PM GMT 31 Jan 2010

The retrenchment follows last week's move by AstraZeneca to slash 8,000 jobs in a five-year restructuring plan, on top of 12,600 cuts already made. The lay-offs at the UK's two largest drugs groups are a blow to one of the last surviving fortresses of British industry, responsible for a quarter of the world's top 100 medicines.

The cuts are a sign that the old strategy of relying on patents and selling "white pills to Western markets" has passed its time as generic drugs sweep global markets.

Glaxo aims to reduce £1.7bn in annual costs by the end of next year and re-focus efforts on research and development. The company has seen lower demand than expected for its Pandremix vaccine against H1N1 swine flu as the virus proved less deadly and contagious than feared at first, though it may yet come back to bite in a mutated form, as the similar Spanish flu virus did in 1919.
The vaccine has lifted sales by around £835m over the last three months but it has not proved a bonanza.

Sales of Glaxo's H1N1 drug Relenza have also fallen short as swine flu fears subside. Germany alone cut its order of Relenza by 30pc earlier this month, costing the company almost £120m in lost sales. France plans to cancel half its expected orders. Britain, Holland, Spain, and Belgium have all been in talks over reductions. In the end, many patients who did come down with the disease needed just one pill instead of two.

Analysts say the group is likely to announce a return to profit growth of around 12pc to £8.69bn at its full-year results on Thursday after an 11pc slip the year before.

The company has been hit by generic versions of its herpes treatment Valtrext after the recent expiry of its US patent, although it has the lupus drug Benlysta wating in the wings. Valtrex sales are expected to drop by two thirds this year to $782m, raising concerns that the group is too reliant on aging patents.

Andrew Witty, the chief executive, is trying to diversify away from its core pharmaceutical business in the West to consumer health, especially in China.

Tougher rules have made it harder to make money in Europe and America. The EU has passed swingeing codes that have pushed key research activities abroad.

The share of the world's clinical trials conducted in the UK fell from 6pc to 2pc between 2000 and 2006, largely due to intrusive regulations that have sharply raised costs.

Pfizer’s Looking for More Sales Reps. In China.

dacare — Wed, 20 Jan 2010 10:38:36 +0800

By Jacob Goldstein

Same song, different verse: A big drug maker is cutting jobs in the developed world and growing in China.

This time, it’s Pfizer, which said today that it’s looking to increase its sales force in China to 3,200 by the end of next year, up from about 2,300, Dow Jones Newswires reported today. The company has said it will cut nearly 20,000 jobs as part of the Wyeth merger.

Eli Lilly said last fall that it would continue to hire in China, even as it cuts jobs in the U.S. and other developed markets. Novartis is also making a big push into China, hiring hundreds of workers and spending $1 billion to expand a research center in Shanghai.

With business tough in developed markets, drug makers are counting on the developing world for growth. But that’s not always a sure thing, either; just today, the WSJ reported that the Philippine government is asking drug makers to submit a list of proposed price cuts on their “top-selling and most expensive drugs.”

Last summer, the government in Manila put price controls on several drugs, including Pfizer’s Norvasc and Lipitor. Pfizer had previously offered to cut the prices on some of its drugs there, and said last year it was “disappointed” that the government didn’t accept its offer.

EMPLOYMENT LAW ALLIANCE EXPANDS PRESENCE IN CHINA

dacare — Fri, 15 Jan 2010 08:13:21 +0800

San Francisco -
Partners from the Beijing, Shanghai, Dalian, Shenzhen and Haikou offices of Jun Le Law Office Join ELA

SAN FRANCISCO – The Employment Law Alliance (ELA) has added five new member offices across China, giving the network an on-the-ground presence in 30 member offices in Asia. The ELA is the world's largest network of more than 3,000 specialized labor and employment lawyers dedicated to assisting employers with legal needs in the U.S. and internationally.

The recent additions are partners from the China-based Jun Le Law Office and include: Dongpeng Wang in the Beijing office, Jianjun Ma in the Shanghai office, Jie Li in the Dalian Office, Xueyong Jiang in the Shenzhen office, and Ruhai Xia in the Haikou office.

“International corporations have long been attracted to China’s extraordinary economic growth and are rapidly opening facilities throughout the country. Ensuring the companies’ policies are compliant with Chinese labor and employment laws is difficult as the laws often vary from city to city,” said Stephen J. Hirschfeld, Esq., CEO of the ELA. “The ELA gives multi-national companies comprehensive, efficient and cost-effective assistance on the ground in each city, region and jurisdiction via truly local experts. We are thrilled to be working with partners at Jun Le as these highly regarded attorneys have intimate knowledge of China’s business practices and employment regulations.”

The ELA offers in-house counsel and human resource executives comprehensive legal guidance in every U.S. state and internationally. Its Global Employer Handbook allows free, 24/7 access to updated legal reference materials and information. The ELA also serves as a resource for trends and issues in employment via its America At Work polls on matters impacting daily business operations around the globe.

“We are pleased to be working collaboratively with our fellow ELA members around the globe. Not only will we be offering our employment law expertise here in China, but our clients with international operations will benefit tremendously from our ability to tap a wealth of reputable legal resources in the vast majority of the world. Not even a global law firm is able to provide such comprehensive experience and coverage,” said Wang.

About The Employment Law Alliance:
The Employment Law Alliance is the world's largest network of labor and employment lawyers. With specialists in all 50 states and more than 100 countries, the ELA provides multi-state and multi-national companies with seamless and cost-effective services worldwide. On the net at: www.employmentlawalliance.com.

Shanghai Overtakes Tokyo as Busiest Asia Stock Market

dacare — Fri, 15 Jan 2010 07:53:00 +0800

Shares worth $5.01 trillion changed hands on the Shanghai Stock Exchange in 2009, compared with $4.07 trillion on the Tokyo Stock Exchange

By Zhang Shidong and Shiyin Chen

(Bloomberg) — Shanghai overtook Tokyo as Asia's biggest stock market by trading value last year, as an 80 percent jump in China's benchmark index boosted equities demand.

Shares worth $5.01 trillion changed hands on the Shanghai Stock Exchange in 2009, compared with $4.07 trillion on the Tokyo Stock Exchange, according to data compiled by Bloomberg. The Shanghai and Tokyo exchanges were ranked third and fourth globally, the Nikkei newspaper reported, citing the World Federation of Exchanges. Only the Nasdaq stock market and the New York Stock Exchange had higher trading volumes than Shanghai.

"As an emerging market, China has a very high ratio of stocks changing hands," said Li Jun, a strategist at Central China Securities Holdings Co. in Shanghai. "Increased new share sales are also one reason behind the high turnover. It'll probably take one year or two for China to catch up with the world's biggest."

The Securities Regulatory Commission on Jan. 8 approved short sales, stock index futures and margin trading. Morgan Stanley said the reforms may boost transaction volume by 50 percent, helping to usher China's market into a "new era."

The Shanghai Composite Index rebounded last year from a 65 percent loss in 2008 after the government introduced a 4 trillion-yuan ($585.9 billion) stimulus package, encouraged banks to advance record loans and subsidized individual purchases of cars and home appliances. Japan's Nikkei 225 Stock Average rose 19 percent.

Shanghai has the world's third largest stock market by market capitalization, briefly overtaking Tokyo in July 2009. New York is the biggest by market cap.

Mainland companies raised 207.6 billion yuan from initial public offerings in 2009, double from the previous year, according to Bloomberg data.

China Overtakes Germany as World's Biggest Exporter

dacare — Mon, 11 Jan 2010 02:45:13 +0800

Chinese officials say the country's exports surged in December to edge out Germany as the world's biggest exporter.

The official Xinhua news agency reported Sunday that figures from the General Administration for Customs showed that exports jumped 17.7 percent in December from a year earlier.

Huang Guohua, a statistics official with the customs administration, said the December exports rebound was an important turning point for China's export sector.

Huang added that the jump was an indication that exporters have emerged from their downslide.

However, although China overtook Germany in exports, China's total foreign trade -- both exports and imports -- fell 13.9 percent in 2009.